Have a feature idea you'd love to see implemented?
Let us know!
ATOS Atossa Therapeutics Inc
Price (delayed)
$1.4
Market cap
$176.06M
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$0.21
Enterprise value
$96.42M
Atossa Therapeutics, Inc. is a clinical-stage biopharmaceutical company seeking to discover and develop innovative medicines in areas of significant unmet medical need with a current focus on breast cancer and
Highlights
The net income has grown by 18% YoY and by 13% from the previous quarter
The company's EPS rose by 16% YoY and by 13% QoQ
The quick ratio has dropped by 51% year-on-year and by 11% since the previous quarter
The company's equity fell by 24% YoY and by 7% QoQ
Key stats
What are the main financial stats of ATOS
Market
Valuations
Earnings
Shares outstanding
125.76M
Market cap
$176.06M
Enterprise value
$96.42M
Price to earnings (P/E)
N/A
Price to book (P/B)
2.2
Price to sales (P/S)
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
Revenue
$0
EBIT
-$25.91M
EBITDA
-$25.88M
Free cash flow
-$18.69M
Per share
Balance sheet
Liquidity
EPS
-$0.21
Free cash flow per share
-$0.15
Book value per share
$0.64
Revenue per share
$0
TBVPS
$0.68
Total assets
$85.86M
Total liabilities
$5.7M
Debt
$0
Equity
$80.16M
Working capital
$76.02M
Debt to equity
0
Current ratio
14.35
Quick ratio
13.98
Net debt/EBITDA
3.08
Margins
Efficiency
Dividend
EBITDA margin
N/A
Gross margin
N/A
Net margin
N/A
Operating margin
N/A
Return on assets
-27.6%
Return on equity
-29.2%
Return on invested capital
-1,181.6%
Return on capital employed
-32.3%
Return on sales
N/A
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
ATOS stock price
How has the Atossa Therapeutics stock price performed over time
Intraday
-1.41%
1 week
-4.76%
1 month
2.94%
1 year
102.9%
YTD
59.09%
QTD
-7.89%
Financial performance
How have Atossa Therapeutics's revenue and profit performed over time
Revenue
$0
Gross profit
$0
Operating income
-$30.57M
Net income
-$25.91M
Gross margin
N/A
Net margin
N/A
The net income has grown by 18% YoY and by 13% from the previous quarter
The operating income rose by 2.2% QoQ and by 2.1% YoY
Growth
What is Atossa Therapeutics's growth rate over time
Valuation
What is Atossa Therapeutics stock price valuation
P/E
N/A
P/B
2.2
P/S
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
The company's EPS rose by 16% YoY and by 13% QoQ
ATOS's P/B is 31% above its last 4 quarters average of 1.7 and 17% above its 5-year quarterly average of 1.9
The company's equity fell by 24% YoY and by 7% QoQ
Efficiency
How efficient is Atossa Therapeutics business performance
ATOS's return on invested capital has dropped by 162% year-on-year and by 36% since the previous quarter
The ROA has increased by 8% from the previous quarter but it has decreased by 3.8% YoY
The return on equity rose by 7% since the previous quarter but it has declined by 6% year-on-year
Dividends
What is ATOS's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for ATOS.
Financial health
How did Atossa Therapeutics financials performed over time
Atossa Therapeutics's total liabilities has surged by 64% YoY and by 7% QoQ
Atossa Therapeutics's current ratio has plunged by 53% YoY and by 12% from the previous quarter
ATOS's debt is 100% smaller than its equity
The company's equity fell by 24% YoY and by 7% QoQ
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise
specified. Data from 
and Sharadar.